Method of treatment with humanized anti-IL-18 antibodies
The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
1. A method of neutralizing IL-18 in an IL-18 mediated disease or disorder in a human in need thereof, said method comprising administering to the human a therapeutically effective amount of an anti-IL1,8 antibody or antigen binding fragment thereof, wherein the anti-IL18 antibody comprises complementarity determining regions (CDRs) selected from the group consisting of:
CDRH1 as set forth in SEQ ID NO: 1;
CDRH2 as set forth in SEQ ID NO: 2;
CDRH3 as set forth in SEQ ID NO: 3;
CDRL1 as set forth in SEQ ID NO: 4;
CDRL2 as set forth in SEQ ID NO: 5; and
CDRL3 as set forth in SEQ ID NO: 6.
2. The method of claim 1 , wherein the anti-IL18 antibody comprises a heavy chain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 11, SEQ ID NO: 19, and SEQ ID NO: 23.
3. The method of claim 1 , wherein the anti-IL18 antibody comprises a light chain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 27, and SEQ ID NO: 31.
4. The method of claim 1 , wherein the anti-IL18 antibody comprises a heavy chain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 11, SEQ ID NO: 19, and SEQ ID NO: 23, and a light chain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 27, and SEQ ID NO: 31.
5. The method of claim 1 , wherein the anti-IL18 antibody comprises a heavy chain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 9, SEQ ID NO: 17, and SEQ ID NO: 21.
6. The method of claim 1 , wherein the anti-IL 18 antibody comprises a light chain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 27, SEQ ID NO: 31, SEQ ID NO: 13, SEQ ID NO: 25, and SEQ ID NO: 29.
7. The method of claim 1 , wherein the anti-IL18 antibody comprises a heavy chain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 9, SEQ ID NO: 17, and SEQ ID NO: 21, and a light chain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 27, SEQ ID NO: 31, SEQ ID NO: 13, SEQ ID NO: 25, and SEQ II) NO: 29.
8. The method of claim 1 , wherein the anti-IL18 antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 11, and a light chain comprising the amino acid sequence shown in SEQ ID NO: 15.
9. The method of claim 1 , wherein the anti-IL18 antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 11 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 15.
10. The method of claim 1 , wherein the anti-IL18 antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 9 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 13.
11. The method of claim 1 , wherein the anti-IL18 antibody is humanized.
12. The method of claim 1 , wherein the disease or disorder is selected from the group consisting of: inflammatory bowel disease (IBD), multiple sclerosis, rheumatoid arthritis, Type 1 diabetes, and psoriasis.
13. The method of claim 1 , wherein the disease or disorder is inflammatory bowel disease (IBD).